MedPath

rTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson's Disease

Not Applicable
Recruiting
Conditions
Impulse Control Disorder
Parkinson Disease
Registration Number
NCT06237868
Lead Sponsor
West Virginia University
Brief Summary

This study's objective is to evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) over the dorsolateral prefrontal cortex (dlPFC) of patients with Parkinson's Disease (PD) who experience impulse control disorders (ICDs) on impulse control symptoms and cognitive behaviors linked to ICDs: reinforcement learning and delay-discounting. This is a randomized sham-controlled cross-over trial. All patients will undergo a session of active rTMS and a session of sham rTMS, with the order of sessions randomized across participants. Following recruitment and eligibility screening, the eligible participants will undergo two sessions of rTMS (active and sham), immediately followed by neurocognitive tasks and questionnaires, no more than 1-2 weeks apart. Each session will have a duration of approximately 1-1.5 hours.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Clinician-confirmed diagnosis of PD
  • Ability to provide informed consent, written and verbal
  • Clinician-diagnosed impulse control disorder or impulse control behaviors including punding/hobbyism and dopamine dysregulation syndrome
  • A Beck Depression Inventory (BDI) (Beck et al., 1961) score of 14 or lower
  • A Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) score of 20 or higher
  • On dopamine-replacement therapy
Exclusion Criteria
  • History of seizures or epilepsy
  • History of brain lesions (such as multiple sclerosis, tumor) reported
  • History of vascular issues in the brain, such as stroke
  • History of a moderate to severe traumatic brain injury
  • Meeting the criteria for a major psychiatric illness such as schizophrenia or depression (BDI score of 14 or higher).
  • Having significant cognitive impairment (assessed by MoCA, cutoff score of 20) (Nasreddine, et al., 2005)
  • Having had TMS done in the recent past (within a year)
  • Pregnancy assessed in female patients
  • Intracranial metallic objects (except for dental fillings)
  • Current use of substances or medications known to significantly reduce seizure threshold.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change in Delay-DiscountingBaseline to 1 hour following the intervention

Change in performance on a task assessing delay-discounting. Delay-discounting assesses the participants' impulsivity by requiring them to make choices between smaller sooner hypothetical money rewards and larger later hypothetical money rewards (e.g. $10 today vs $100 in a year). This is a hypothetical choice, and the participant will not be receiving the chosen rewards. A short preliminary version of the task will be completed at the start of the first session (prior to TMS) to optimize task parameters for each participant. The task will be completed on a laptop computer.

Change in Reinforcement LearningBaseline to 1 hour following the intervention

Change in performance on a task assessing reinforcement learning. The reinforcement learning task assesses how well participants learn from rewards vs. punishments. The task will ask participants to choose from two stimuli that predict reward (gaining points) or punishment (losing points) at different rates, which they will learn in the course of the task based on feedback. At the end of the task, participants will be asked to rate how well each stimulus predicted reward or punishment.

Secondary Outcome Measures
NameTimeMethod
Change in impulse control disorder symptomsBaseline to 1 hour following the intervention

Change in impulse control disorder symptoms measured using a modified version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS). QUIP-RS is a self-administered assessment of impulsive and compulsive behaviors in patients with PD. The QUIP-RS is a brief 28-item patient-reported or clinician-rated scale that was developed in PD and derived from the QUIP to measure of severity of ICDs. Each item is rated on a 5-point Likert scale assessing the frequency of symptoms with a range of scores from 0 (never) to 4 (very often).

Trial Locations

Locations (1)

West Virginia University Hospitals

🇺🇸

Morgantown, West Virginia, United States

West Virginia University Hospitals
🇺🇸Morgantown, West Virginia, United States
Mariya V Cherkasova, PhD
Contact
2403673068
mariya.cherkasova@mail.wvu.edu

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.